The favorable 52-week risk–benefit profile of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis merits consideration of this administration route and of an ...

SAN FRANCISCO, CA—Methotrexate is frequently under-dosed, administered for an inadequate duration, and rarely switched to subcutaneous injection prior to initiating biologic therapy, James R. O’Dell, ...

Methotrexate The effectiveness of oral vs subcutaneous methotrexate for the treatment of psoriasis in a registry is reported. More patients with psoriasis who were treated with subcutaneous ...

“Because so many RA patients have limited manual dexterity, conventional syringes for injection of methotrexate are often difficult to use. An easy delivery system that combines subcutaneous ...

Please provide your email address to receive an email when new articles are posted on . LONDON — Patients with moderate to severe rheumatoid arthritis who receive early treatment with subcutaneous ...

Please provide your email address to receive an email when new articles are posted on . Subcutaneous methotrexate is safe in clinical practice, and is continued longer and better tolerated than other ...

Physicians are underutilizing methotrexate, the leading drug for rheumatoid arthritis (RA), or not keeping patients on the drug long enough before switching them to more expensive biologic drug ...

A multicentre, prospective cohort study comparing the effectiveness of oral versus subcutaneous methotrexate in patients with early rheumatoid arthritis (RA) found subcutaneous therapy to be ...

TOKYO, Feb 16, 2024 - (JCN Newswire) - - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained ...

The US Food and Drug Administration (FDA) has approved a subcutaneous injectable methotrexate delivered in an auto-injector (Rasuvo, Medac Pharma) for rheumatoid arthritis (RA), polyarticular-course ...

Methotrexate significantly lowers systolic blood pressure in newly diagnosed RA patients compared to sulfasalazine, potentially reducing cardiovascular risk. The study provides prospective comparative ...